Pennsylvania Advances Bill Allowing Medical Marijuana in Hospitals

Legislative Action and Timeline

The Pennsylvania House of Representatives advanced the hospital access bill through committee on September 29, 2026. The measure now moves to the full House for consideration. If passed, Pennsylvania would join a small group of states explicitly authorizing medical cannabis use within hospital settings for end-of-life patients.

The bill addresses a longstanding conflict between state medical marijuana law and federal healthcare facility regulations. Most Pennsylvania hospitals currently prohibit medical cannabis on premises due to federal Schedule I status and concerns about Medicare/Medicaid funding.

What the Bill Changes

The legislation would create a legal pathway for terminally ill patients enrolled in Pennsylvania's Medical Marijuana Program to possess and use state-approved cannabis products while admitted to hospitals, hospice facilities, and nursing homes. Key provisions include:

• Limits eligibility to patients with terminal diagnoses and existing medical marijuana certifications
• Requires patient consent and physician approval for each instance of use
• Permits only state-licensed medical marijuana products in approved forms
• Shields facilities from state penalties for allowing compliant use
• Does not require facilities to permit use—participation remains voluntary

Federal liability concerns remain unaddressed. The bill doesn't touch Medicare or Medicaid reimbursement protections.

Current Access Barriers

Pennsylvania's existing Medical Marijuana Act, enacted in 2016, doesn't explicitly address use in healthcare facilities. This omission has created a patchwork of institutional policies. Most hospitals prohibit possession entirely, forcing patients to leave premises or forgo medication during critical treatment windows.

Patient advocates have documented cases where terminally ill individuals discontinued medical cannabis during final hospitalizations due to facility restrictions, despite state certification for conditions including cancer, chronic pain, and nausea.

Facility Implementation Questions

Even if the bill becomes law, hospital participation will be voluntary. Federal compliance risks remain unresolved. Pennsylvania hospitals that accept Medicare or Medicaid funding—virtually all acute-care facilities—operate under federal oversight, and the Centers for Medicare & Medicaid Services hasn't issued guidance on state medical marijuana programs in hospital settings.

Industry observers expect most large health systems to wait for federal rescheduling or explicit CMS guidance before changing policies. Smaller hospice and palliative-care facilities may move faster.

Stakeholder Positions

Patient advocacy groups strongly support the measure, while hospital associations have expressed cautious neutrality. The Pennsylvania Medical Cannabis Society called the bill a necessary compassion measure. The Hospital & Healthsystem Association of Pennsylvania hasn't taken a formal position but noted operational and legal concerns in committee testimony.

No organized opposition has emerged. Law enforcement groups haven't weighed in. The Pennsylvania Department of Health has signaled it would implement the law if passed.

National Context and Pennsylvania's Program

Pennsylvania operates one of the nation's largest medical marijuana programs, with over 400,000 active patient certifications as of mid-2026. The state licenses approximately 200 dispensaries and permits cannabis for 23 qualifying conditions. Terminal illness isn't listed as a standalone condition, but most end-of-life patients qualify under cancer, chronic pain, or other approved diagnoses.

For complete regulatory background, see the CannIntel topic hub on Pennsylvania's Medical Marijuana Program.

Nationally, fewer than five states have enacted explicit hospital-access provisions for medical cannabis patients. Most medical marijuana laws are silent on institutional use, leaving policy to individual facilities. State legislators likely didn't anticipate the federal-state conflict when drafting early medical cannabis statutes.